Do analysts prefer GENF or HVO?

hVIVO has a consensus target price of GBX 16.33, suggesting a potential upside of 181.12%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than Genflow Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genflow Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is GENF or HVO more profitable?

hVIVO has a net margin of -31.76% compared to Genflow Biosciences' net margin of -148.10%. Genflow Biosciences' return on equity of 224.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets Genflow Biosciences -148.10% 224.00% -58.66% hVIVO -31.76% -35.13% 11.97%

Does the media prefer GENF or HVO?

In the previous week, hVIVO had 5 more articles in the media than Genflow Biosciences. MarketBeat recorded 6 mentions for hVIVO and 1 mentions for Genflow Biosciences. hVIVO's average media sentiment score of 0.47 beat Genflow Biosciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genflow Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral hVIVO 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, GENF or COIL?

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genflow Biosciences N/A N/A -£1.76M -£0.22 N/A Roquefort Therapeutics N/A N/A -£1.52M -£20.24 N/A

Which has better valuation & earnings, IMM or GENF?

Genflow Biosciences is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuPharma N/A N/A -£2.51M -£0.83 N/A Genflow Biosciences N/A N/A -£1.76M -£0.22 N/A

Genflow Biosciences (GENF) Competitors

GBX 1.78 -0.02 (-1.22%)

As of 09:58 AM Eastern

Compare

GENF vs. HVO, C4XD, DDDD, COIL, and IMM

Should you buy Genflow Biosciences stock or one of its competitors? Genflow Biosciences's main competitors and comparable companies include hVIVO (HVO), C4X Discovery (C4XD), 4D pharma (DDDD), Roquefort Therapeutics (COIL), and ImmuPharma (IMM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to hVIVO?

Genflow Biosciences (LON:GENF) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 12.7% of hVIVO shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Comparatively, 4.9% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

hVIVO has a net margin of -31.76% compared to Genflow Biosciences' net margin of -148.10%. Genflow Biosciences' return on equity of 224.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genflow Biosciences	-148.10%	224.00%	-58.66%
hVIVO	-31.76%	-35.13%	11.97%

Genflow Biosciences has a beta of 2.285, indicating that its share price is 129% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.694, indicating that its share price is 69% more volatile than the broader market.

hVIVO has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genflow Biosciences	N/A	N/A	-£1.76M	-£0.22	N/A
hVIVO	£38.85M	1.03	£17.84M	-£1.78	N/A

In the previous week, hVIVO had 5 more articles in the media than Genflow Biosciences. MarketBeat recorded 6 mentions for hVIVO and 1 mentions for Genflow Biosciences. hVIVO's average media sentiment score of 0.47 beat Genflow Biosciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genflow Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
hVIVO	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

hVIVO has a consensus target price of GBX 16.33, suggesting a potential upside of 181.12%. Given hVIVO's stronger consensus rating and higher probable upside, analysts clearly believe hVIVO is more favorable than Genflow Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genflow Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

hVIVO beats Genflow Biosciences on 11 of the 15 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.285, indicating that its stock price is 129% more volatile than the broader market.

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4X Discovery	£24.68M	0.00	£10.57M	£0.04	N/A
Genflow Biosciences	N/A	N/A	-£1.76M	-£0.22	N/A

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -148.10%. Genflow Biosciences' return on equity of 224.00% beat C4X Discovery's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4X Discovery	42.81%	55.38%	28.04%
Genflow Biosciences	-148.10%	224.00%	-58.66%

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 27.1% of C4X Discovery shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Genflow Biosciences had 1 more articles in the media than C4X Discovery. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for C4X Discovery. C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company	Overall Sentiment
C4X Discovery	Neutral
Genflow Biosciences	Neutral

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

Genflow Biosciences (LON:GENF) and 4D pharma (LON:DDDD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

4D pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -148.10%. Genflow Biosciences' return on equity of 224.00% beat 4D pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genflow Biosciences	-148.10%	224.00%	-58.66%
4D pharma	N/A	-89.48%	-42.64%

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 26.8% of 4D pharma shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Comparatively, 12.2% of 4D pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Genflow Biosciences had 1 more articles in the media than 4D pharma. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for 4D pharma. Genflow Biosciences' average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.

Company	Overall Sentiment
Genflow Biosciences	Neutral
4D pharma	Neutral

Genflow Biosciences has higher earnings, but lower revenue than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genflow Biosciences	N/A	N/A	-£1.76M	-£0.22	N/A
4D pharma	£718K	0.00	-£31.94M	-£15.40	N/A

Genflow Biosciences has a beta of 2.285, indicating that its share price is 129% more volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, indicating that its share price is 163% more volatile than the broader market.

Summary

4D pharma beats Genflow Biosciences on 6 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Genflow Biosciences (LON:GENF) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Genflow Biosciences has a beta of 2.285, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

Genflow Biosciences has a net margin of -148.10% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 224.00% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genflow Biosciences	-148.10%	224.00%	-58.66%
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genflow Biosciences	N/A	N/A	-£1.76M	-£0.22	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£20.24	N/A

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by insiders. Comparatively, 36.3% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Genflow Biosciences had 1 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for Roquefort Therapeutics. Genflow Biosciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genflow Biosciences	Neutral
Roquefort Therapeutics	Neutral

Summary

Genflow Biosciences and Roquefort Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to ImmuPharma?

ImmuPharma (LON:IMM) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

ImmuPharma has a beta of 3.017, meaning that its stock price is 202% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.285, meaning that its stock price is 129% more volatile than the broader market.

ImmuPharma has a net margin of 3,519.56% compared to Genflow Biosciences' net margin of -148.10%. Genflow Biosciences' return on equity of 224.00% beat ImmuPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuPharma	3,519.56%	-559.87%	-43.00%
Genflow Biosciences	-148.10%	224.00%	-58.66%

Genflow Biosciences is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuPharma	N/A	N/A	-£2.51M	-£0.83	N/A
Genflow Biosciences	N/A	N/A	-£1.76M	-£0.22	N/A

In the previous week, Genflow Biosciences had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for ImmuPharma. ImmuPharma's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company	Overall Sentiment
ImmuPharma	Neutral
Genflow Biosciences	Neutral

6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 6.2% of ImmuPharma shares are held by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ImmuPharma and Genflow Biosciences tied by winning 5 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENF vs. The Competition

Export

Metric	Genflow Biosciences	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£10.57M	£3.88B	£7.25B	£2.80B
Dividend Yield	N/A	3.65%	2.52%	6.26%
P/E Ratio	-8.08	13.03	275.44	366.78
Price / Sales	N/A	1,148.01	562.05	88,865.26
Price / Cash	3.00	118.50	77.16	27.85
Price / Book	7.16	16.75	10.64	7.07
Net Income	-£1.76M	-£22.65M	£3.49B	£5.89B
7 Day Performance	1.02%	-4.89%	-3.21%	0.25%
1 Month Performance	-15.33%	-12.84%	-7.65%	-0.03%
1 Year Performance	-6.42%	7.43%	2.92%	22.90%

Genflow Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENF Genflow Biosciences	N/A	GBX 1.78 -1.2%	N/A	-6.5%	£10.57M	N/A	N/A	5	Gap Up
HVO hVIVO	1.8164 of 5 stars	GBX 5.89 -0.2%	GBX 16.33 +177.3%	-25.5%	£40.55M	£38.85M	N/A	N/A	Analyst Forecast
C4XD C4X Discovery	N/A	N/A	N/A	N/A	£30.27M	£24.68M	300.00	49	High Trading Volume
DDDD 4D pharma	N/A	N/A	N/A	N/A	£30.05M	£718K	N/A	106
COIL Roquefort Therapeutics	N/A	GBX 7 +3.7%	N/A	-70.0%	£29.88M	N/A	N/A	9	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genflow Biosciences (GENF) Competitors

GENF vs. HVO, C4XD, DDDD, COIL, and IMM

How does Genflow Biosciences compare to hVIVO?

Summary

How does Genflow Biosciences compare to C4X Discovery?

Summary

How does Genflow Biosciences compare to 4D pharma?

Summary

How does Genflow Biosciences compare to Roquefort Therapeutics?

Summary

How does Genflow Biosciences compare to ImmuPharma?

Summary

Media Sentiment Over Time

GENF vs. The Competition

Genflow Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genflow Biosciences (GENF) Competitors

GENF vs. HVO, C4XD, DDDD, COIL, and IMM

How does Genflow Biosciences compare to hVIVO?

Do institutionals and insiders have more ownership in GENF or HVO?

Is GENF or HVO more profitable?

Which has more risk & volatility, GENF or HVO?

Which has preferable valuation & earnings, GENF or HVO?

Does the media prefer GENF or HVO?

Do analysts prefer GENF or HVO?

Summary

How does Genflow Biosciences compare to C4X Discovery?

Which has more volatility & risk, C4XD or GENF?

Which has preferable valuation & earnings, C4XD or GENF?

Is C4XD or GENF more profitable?

Do insiders and institutionals have more ownership in C4XD or GENF?

Does the media refer more to C4XD or GENF?

Summary

How does Genflow Biosciences compare to 4D pharma?

Is GENF or DDDD more profitable?

Do institutionals & insiders hold more shares of GENF or DDDD?

Does the media prefer GENF or DDDD?

Which has stronger earnings & valuation, GENF or DDDD?

Which has more risk and volatility, GENF or DDDD?

Summary

How does Genflow Biosciences compare to Roquefort Therapeutics?

Which has more risk & volatility, GENF or COIL?

Is GENF or COIL more profitable?

Which has preferable valuation and earnings, GENF or COIL?

Do insiders & institutionals have more ownership in GENF or COIL?

Does the media prefer GENF or COIL?

Summary

How does Genflow Biosciences compare to ImmuPharma?

Which has more risk & volatility, IMM or GENF?

Is IMM or GENF more profitable?

Which has better valuation & earnings, IMM or GENF?

Does the media refer more to IMM or GENF?

Do insiders & institutionals believe in IMM or GENF?

Summary

Media Sentiment Over Time

GENF vs. The Competition

Genflow Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools